Voglilviga M 0.2 Tablet is a bilayered smart formulation combining Metformin (500mg) in sustained-release (SR) form with Voglibose (0.2mg), designed to offer a dual mechanism for controlling blood glucose levels in patients with Type 2 Diabetes Mellitus. This combination supports improved glycemic control by targeting both fasting and postprandial blood sugar levels.
Metformin, a cornerstone in antidiabetic therapy, belongs to the biguanide class and works by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. Its sustained-release formulation ensures a steady release into the bloodstream, which helps maintain stable glucose levels while minimizing gastrointestinal side effects.
Voglibose is an alpha-glucosidase inhibitor that acts locally in the small intestine. It delays the absorption of carbohydrates by inhibiting the enzymes responsible for breaking down complex sugars. This action effectively reduces post-meal blood glucose spikes, which are often a challenge in Type 2 diabetes management.
The bilayered smart tablet design ensures optimal delivery and release kinetics of both active ingredients, allowing them to work in synergy. While Metformin addresses baseline and fasting glucose, Voglibose works on controlling glucose spikes after meals—providing comprehensive glycemic management.
Voglilviga M 0.2 is especially beneficial for newly diagnosed diabetic patients or those whose blood sugar levels are inadequately controlled by Metformin or Voglibose alone. Regular use, combined with appropriate diet, exercise, and lifestyle changes, significantly improves overall glycemic control and reduces the risk of diabetes-related complications.
Patients are advised to take this tablet with meals to enhance tolerability and effectiveness. Routine monitoring of blood sugar levels, kidney function, and adherence to a diabetic care plan is essential for optimal outcomes.